Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: YK-11 evidence and protocol review
Also known as: YK11
YK-11 is a synthetic steroidal selective androgen receptor modulator (SARM), first characterized in 2011 by Japanese researcher Yuhei Kanno. Unlike typical SARMs, it acts as a partial androgen receptor agonist while uniquely suppressing myostatin activity by upregulating follistatin expression in muscle cells, promoting myogenic differentiation in vitro (C2C12 myoblast studies). Despite several published mechanistic/analytical-chemistry studies (in vitro cell studies, doping-control mass-spectrometry characterization, and equine metabolism studies for anti-doping purposes), YK-11 has not been studied in humans or even in whole-animal (in vivo) models - its safety, pharmacokinetics, and long-term effects remain entirely uncharacterized at anything beyond the cell-culture level. Despite this near-total absence of safety data, research has documented a marked surge in unsupervised human use between 2020-2022, with users tending to exceed even the arbitrary doses used in the limited available cell studies - a genuinely alarming risk profile that should be represented plainly rather than softened.
Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.
Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
YK-11 has no validated human dosing or safety data and is not an approved SARM. Hepatic, endocrine, cardiovascular, and product-contamination risks are unresolved.
Supplementary research context only. Not medical advice or a treatment recommendation.
Best-effort summary of forum/Reddit discussion. This is anecdotal community commentary, not a scientific source, and does not count toward this record's verification status. Do not treat it as established fact or medical guidance.
Community discussion of YK-11 (a myostatin-inhibiting SARM-like compound) includes multiple reports of concerning adverse effects, including CNS strain and elevated blood pressure, alongside general side-effect discussion; considered one of the higher-risk compounds discussed in these communities. Anecdotal, not clinically verified.
User reports significant CNS strain and elevated blood pressure attributed to YK-11 use, warning others to be cautious; an isolated adverse-event-style report, not corroborated by clinical data.
Community discussion thread specifically about YK-11 side effects; anecdotal, self-reported.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.